Glutethimide scheduling

Executive Summary

The Drug Enforcement Administration proposes to transfer glutethimide from Schedule III to Schedule II of the Controlled Substances Act in a July 26 Federal Register notice. The action is based on evidence of abuse and diversion of the drug and on the recommendation of the Assistant Secretary for Health. Comments must be submitted by Sept. 24. FDA's Drug Abuse Advisory Committee recommended that the hypnotic sedative be moved to Schedule II ("The Pink Sheet" June 11, T&G-4). A number of generic firms manufacture the drug.